Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.
Warner PostmaEnrico FabrisMartin Van der EntRik HermanidesPawel BuszmanClemens von BirgelenStéphane CookHans WedelGiuseppe De LucaRonak DelewiFelix ZijlstraElvin KedhiPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- end stage renal disease
- acute coronary syndrome
- ejection fraction
- coronary artery disease
- newly diagnosed
- chronic kidney disease
- study protocol
- prognostic factors
- peritoneal dialysis
- phase iii
- patient reported outcomes
- drug induced
- double blind